Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1-Reference-Cited by-同舟云学术

Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

Published:2015-12-01 Issue:9 Volume:1 Page:1319
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Howitt Brooke E.¹,Shukla Sachet A.²,Sholl Lynette M.¹,Ritterhouse Lauren L.¹,Watkins Jaclyn C.¹,Rodig Scott¹,Stover Elizabeth³,Strickland Kyle C.¹,D’Andrea Alan D.⁴,Wu Catherine J.²,Matulonis Ursula A.³,Konstantinopoulos Panagiotis A.³

Affiliation:

1. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

2. Broad Institute of Harvard and MIT, Cambridge, Massachusetts3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

3. Medical Gynecologic Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

4. Division of Genomic Stability and DNA Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 536 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic subtypes and cellular phenotypes of high-grade endometrial carcinoma;2024-09-04

2. Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges;Cancer Letters;2024-09

3. Prognostic Significance of the Immune Microenvironment in Endometrial Cancer;Laboratory Investigation;2024-09

4. ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer;Annals of Oncology;2024-09

5. Clinicopathological and immune characterization of mismatch repair deficient endocervical adenocarcinoma;The Oncologist;2024-08-07